EpOME, epoxyoctadecaenoic acid; FDR, false discovery rate; LLOQ, lower limit of quantification; LOX, lipoxygenase; MCP-1, monocyte chemoattractant protein-1; NSTEMI, non ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PGE2, prostaglandin E 2 ; PI3K, .003) such that the presence of obstructive CAD was associated with lower circulating EET levels. This relationship was confirmed in multiple regression analysis where CAD extent was inversely and significantly associated with EET levels (P=0.013), and with a biomarker of EET biosynthesis (P<0.001), independent of clinical and demographic factors. Furthermore, quantitative enrichment analysis revealed that these associations were the most pronounced compared to other eicosanoid metabolism pathways.
Introduction
Despite significant advances in its treatment, coronary artery disease (CAD) remains the leading cause of morbidity and mortality worldwide (1) . Consequently, new therapeutic strategies are needed to further improve outcomes. The discovery of biomarkers involved in the pathogenesis of CAD offers considerable promise to facilitate the development of novel therapeutics and identify subsets of high-risk patients who may derive the greatest benefit from therapy (2) .
In addition to their role as xenobiotic metabolizing enzymes, cytochromes P450 (CYP) metabolize fatty acids to bioactive lipids that regulate numerous cellular and physiologic processes relevant to the pathogenesis of CAD (3) . Most notably, CYP epoxygenases from the CYP2C and CYP2J subfamilies metabolize arachidonic acid (AA) into four epoxyeicosatrienoic acid (EET) regioisomers (5,6-, 8,9-, 11,12-and 14,15-EET) with varying regioselectivity (4) . The EETs elicit potent vasodilatory, antiinflammatory and cellular protective effects in the cardiovascular system, but are rapidly hydrolyzed by soluble epoxide hydrolase (sEH, EPHX2) into dihydroxyeicosatrienoic acids (DHETs) (5, 6) .
Promoting the effects of EETs yields potent cardiovascular protective effects in preclinical models of vascular inflammation, atherosclerosis, and myocardial ischemia-reperfusion injury (5) (6) (7) . In epidemiologic studies, associations between functional polymorphisms in genes responsible for EET biosynthesis (CYP2C8, CYP2J2) or EET hydrolysis (EPHX2) and the development of CAD have been reported (8) (9) (10) . Taken together, these data suggest that increasing CYP-derived EET levels may be a viable therapeutic strategy for CAD. However, since EETs are not measured on traditional metabolomic or eicosanoid analytical platforms (11) , major gaps in knowledge surrounding the biologic and therapeutic importance of EETs in human CAD exist. Quantifying EET metabolite levels offers the potential to identify key factors that impact EET biosynthesis and EET hydrolysis, beyond germline genetic polymorphisms, and facilitate the rational design of clinical trials with emerging therapies that target the EET metabolic pathway. 
Materials and Methods

Study population
A cohort of individuals 18-80 years of age referred for coronary angiography to detect new or worsening CAD were identified in the cardiac catheterization laboratories at the University of North CarolinaChapel Hill between September 2012 and February 2014. Exclusion criteria included severe concurrent illness (such as active pneumonia or acute decompensated heart failure), systemic inflammatory disease (such as rheumatoid arthritis), cancer actively being treated, hematologic disorders affecting platelet function, prior heart transplantation, hematocrit <30%, ST segment elevation myocardial infarction (STEMI), end-stage liver disease, end-stage renal disease on dialysis, and systemic immunosuppressive medication use (such as corticosteroid use). Eligible participants provided written informed consent. The study protocol was approved by the UNC Biomedical Institutional Review Board.
Whole blood was drawn in the catheterization lab from the indwelling arterial sheath after it had been placed as part of the coronary angiography procedure, but before initiation of a revascularization procedure (if indicated). Plasma was immediately separated by centrifugation and stored at -80°C.
Classification of CAD extent
The extent of CAD was classified based on the results of the coronary angiography. Obstructive CAD was defined according to the anatomical or physiological 'criteria for revascularization' from recent clinical practice guidelines (12) . Briefly, the anatomic criteria for revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafts [CABG] ) are the presence of ≥50% stenosis in the left main coronary artery or ≥70% stenosis in one or more of the non-left main coronary arteries.
The classification of nonobstructive CAD included those without obstructive CAD that had mild stenosis (10-69% in one or more non-left main coronary arteries and/or 10-49% stenosis in the left main coronary artery), whereas the classification of no apparent CAD included those with no angiographic evidence of CAD (<10% stenosis in all coronary arteries). Only unprotected lesions (lesions not bypassed by by guest, on September 21, 2017 www.jlr.org Downloaded from collateral vessels, bypass grafts, or stents) in native coronary arteries were considered for classification in order to reflect the current extent of coronary artery stenosis at the time of blood sampling that was unrelated to a prior revascularization procedure.
Quantification of eicosanoid metabolite concentrations
Free plasma eicosanoid metabolite concentrations were quantified using a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method with optimized sensitivity and specificity for EET quantification, as previously described with minor modifications (13, 14) . Briefly, plasma (0.25 mL) was diluted in 0.1% acetic acid/5% methanol solution (0.25 mL) containing 0.009 mM butylated hydroxytoluene (BHT), spiked with internal standards ( to isolate lipids. Extracts in ethyl acetate were then dried by centrifugation under vacuum, covered in argon, and stored at -80°C for future processing. Dried extracts were reconstituted in 80% methanol (containing 10mg/ml BHT) for elution through phospholipid removal columns (Phree, Phenomenex, Torrance, CA), as directed by the manufacturer. Phospholipid removal enhances purification of the extracts, thereby reducing matrix ion suppression and improving signal:noise ratio (16) . Phospholipid-free extracts were then dried a second time by centrifugation under vacuum and stored at -80°C. At the time of analysis, extracts were reconstituted in 50 μL of 30% ethanol and a panel of 34 eicosanoid metabolites (Supplementary Table S1 ) was quantified by targeted LC/MS/MS, as previously described (13, 14) .
Concentration values falling below the lower limit of quantitation were imputed as a concentration equal to half of the lowest standard. Analytes with more than 50% of the values below or above the lower or upper limit of quantitation, respectively, were not included in the analysis (Supplementary Table S1 ) (13) .
Among the 28 metabolites that met these criteria, 24 of 28 (86%) had <10% values out of the quantitation and February 2014. Briefly, blood (5ml) was centrifuged over a density gradient medium (Lymphoprep, Axis Shield, Oslo, Norway). Cells were collected at the interface, washed with cold PBS, and homogenized. Total RNA was isolated using the RNeasy Miniprep kit (Qiagen, Valencia, CA), and reverse transcribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA).
Expression of CYP2J2 (Hs00356035_m1) and EPHX2 (Hs00157403_m1) was quantified using Taqman Assays on Demand (Applied Biosystems, Foster City, CA), and calculated relative to GAPDH (Hs02758991_g1) using the 2 -∆Ct method, as previously described (17) .
Time-to-event analysis of cardiovascular outcomes
The incidence of future cardiovascular events was abstracted from the electronic medical record from the time of the index angiography through August 2014. Those who did not present to the UNC health care system for routine follow-up or emergent care after the index coronary angiography visit were considered to be lost to follow-up and were excluded from the analysis. The prespecified primary endpoint was the time to the first occurrence of death due to a cardiovascular cause, hospitalization for a non-fatal acute coronary syndrome (ACS) event (unstable angina, non ST segment elevation myocardial infarction
[NSTEMI], STEMI), or hospitalization for a coronary revascularization procedure (PCI or CABG).
Clinician reported outcomes were verified from the electronic medical records by two individuals.
Statistical analysis
Data are presented as mean ± standard deviation, median (interquartile range), or count (%). All analyses were performed using SAS 9. Metabolite levels and epoxide:diol ratios were not normally distributed and thus log-transformed prior to statistical analysis. Pearson correlations between individual metabolites were evaluated. Significant correlations were observed among the EET as well as the DHET regioisomers (Supplemental Figure S1 ).
Thus, to minimize redundancy, the sum of the 8, Figure S1) . In order to determine the most enriched eicosanoid metabolic pathways across obstructive CAD status, metabolites were then assigned to 9 distinct eicosanoid metabolic pathways according to their parent substrate and biosynthesis enzyme. QEA was conducted to determine the relative impact of obstructive CAD on the 9 eicosanoid metabolic pathways. The relationship between baseline CAD extent and time to occurrence of the primary endpoint (cardiovascular death, non-fatal ACS event, coronary revascularization) was assessed with Cox proportional hazards regression. Due to a low number of events in those with no apparent (0 events) or nonobstructive (4 events) CAD, the association between baseline EET levels (tertiles) and the primary endpoint was explored exclusively within the obstructive CAD patients. Due to the low number of events, time-to-event analyses were unadjusted. Kaplan-Meier curves were generated using GraphPad Prism 6.0.
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Results
Study population
The demographic and clinical characteristics of the study population are shown in Table 1 . Of 162 participants, 72 (44%) were diagnosed with obstructive CAD, 51 (31%) were diagnosed with nonobstructive CAD, and 39 (24%) exhibited no apparent CAD. Several indices of CAD burden were significantly more prevalent with increasing CAD extent including history of a prior revascularization procedure (P=0.009) and diagnosis of an ACS during the index visit (P<0.001). The prevalence of CAD risk factors and medication use were comparable to previously reported coronary angiography cohorts and reflected clinical practice guidelines (12, 20) . Cholesterol and triglyceride levels did not significantly differ across CAD extent.
Association of EET metabolic pathway biomarkers and CAD extent
The sum of free EET levels in plasma were inversely associated with CAD extent, such that EET levels in obstructive CAD patients were lower than EET levels in patients with either no apparent CAD or nonobstructive CAD ( Figure 1a , Table 2 ). Sum EET levels significantly differed between no apparent CAD and obstructive CAD patients (P<0.05), whereas the observed difference in EET levels between nonobstructive CAD and obstructive CAD patients was not statistically significant after adjusting for covariates (P=0.063). No difference in EET levels were observed between patients with no apparent CAD and nonobstructive CAD. Consistent results were observed with the individual 8,9-, 11,12-and 14,15-EET regioisomers and the DHET metabolites (Table 2) . Furthermore, higher maximum coronary artery stenosis (another indicator of CAD extent: the percent narrowing of the most obstructed coronary artery) was significantly associated with lower sum EETs (Pearson's r=-0.26, P=0.001).
A similar inverse relationship was observed between CAD extent and free EETs+DHETs ( Figure 1b , Table 2 ). In addition, mRNA levels of the CYP epoxygenase enzyme CYP2J2 in PBMCs were inversely associated with CAD extent (P=0.042; Supplemental Figure S2a ). In contrast, the 14,15-EET:DHET ratio by guest, on September 21, 2017
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was not significantly associated with CAD extent ( Figure 1c , Table 2 ). Similarly, no association was observed between CAD extent and either the sum EET:DHET ratio (Table 2) or the 12,13-EpOME:DHOME ratio biomarkers of sEH metabolic function (P=0.992), or EPHX2 mRNA levels in PBMCs (P=0.320; Supplemental Figure S2b ).
The multivariate analysis demonstrated that CAD extent was a significant independent predictor of EET levels ( Table 3 ). The presence of collaterals, compensatory anastomotic bypasses between or within coronary arteries without an intervening capillary bed (21), was also associated with lower EET levels.
Moreover, use of certain medications was associated with higher (statins, calcium channel blockers) and lower (beta blockers, angiotensin-converting enzyme inhibitors) EET levels ( Table 3) . CAD extent was also a significant independent predictor of sum EETs+DHETs levels ( Table 4) .
Identification of altered eicosanoid pathways across obstructive CAD status
Among all of the individual eicosanoid metabolites quantified, 11 were altered (P<0.05) between obstructive CAD patients (N=72) and all other participants (N=90) (Figure 2a and 2b; Table 5 ). The three EET and four DHET regioisomers were among the 11 analytes associated with CAD extent. QEA revealed that only the AA-derived CYP epoxide and AA-derived sEH diol pathways were significantly associated with the presence of obstructive CAD ( Figure 2c ; Table 6 ).
Risk of future cardiovascular events
Follow-up data was available in 121 (75%) of the enrolled participants, and the median length of followup was 1.0 years. Cardiovascular death, a non-fatal ACS event or a coronary revascularization procedure occurred in 21 participants (0, 10, and 11 events, respectively). CAD extent at baseline was significantly associated with incidence of a cardiovascular event, with 17 of the 21 events occurring in those with obstructive CAD (Figure 3a ), similar to previous studies (20) .
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Discussion
This is the first study that reports a relationship between circulating EET metabolite levels and the angiographic extent of CAD in humans. We observed that the presence of obstructive CAD is significantly and independently associated with lower plasma free (unesterified) EET levels. Furthermore, the association between obstructive CAD and lower EET levels (a) correlates with lower CYP epoxygenase metabolic function, but not higher sEH metabolic function and (b) is significantly more pronounced than other eicosanoid metabolism pathways. Collectively, these findings suggest that the presence of obstructive CAD is associated with lower EET metabolite levels secondary to suppressed EET biosynthesis. Based on these findings, the authors suggest that novel strategies that promote the pathways. Taken together, these findings suggest that CYP-derived EETs may play an important role in the pathogenesis and progression of CAD in humans.
In the current study, CAD extent was also associated with lower sum EETs+DHETs in plasma and CYP2J2 expression in PBMCs, but not altered plasma EET:DHET ratios or EPHX2 expression. These data suggest that the inverse association between EET levels and CAD extent was mediated by suppression of EET biosynthesis (CYP epoxygenase metabolism), and not an increase in EET hydrolysis (sEH metabolism). Accordingly, it is well-established that inflammatory stimuli suppress CYP-mediated xenobiotic metabolism through a variety of mechanisms, including cytokine-mediated transcriptional downregulation of CYP expression (27); fittingly, inflammatory stimuli also drive the development and progression of CAD (28 The relationship between metabolite biomarkers of the EET metabolic pathway and prognosis in patients with established CAD has not been studied to date. Therefore, we explored the relationship between baseline EET levels and risk of a future adverse cardiovascular event in patients with obstructive CAD at baseline. We observed an inverse relationship across the EET tertiles where the highest event incidence occurred in those with the lowest EET levels at baseline. This relationship was not statistically significant and should be interpreted with caution due to the small number of events. These findings, however, are biologically plausible considering the anti-inflammatory and protective effects of EETs in numerous preclinical models of cardiovascular disease. Furthermore, these data are consistent with a previously reported inverse association between circulating EET and monocyte chemoattractant protein-1 (MCP-1)
concentrations (a pro-inflammatory chemokine predictive of poor prognosis in CAD (43)), in which patients with stable CAD in the lowest and middle EET tertiles had significantly higher MCP-1 levels compared to those in the highest EET tertile (18) . These preliminary observations underscore the need to rigorously evaluate the relationship between EET levels and the risk of cardiovascular events in larger populations.
Although the current study is the largest to date evaluating the relationship between CYP-derived eicosanoid metabolites and CAD in humans, our analysis has limitations that must be acknowledged. Due to the cross-sectional design of the present study, causality between plasma EET levels and CAD extent cannot be established. Consequently, we are unable to discern whether low EET levels result from the presence of obstructive CAD or whether low EET levels are a causal factor in the development of found in low abundance in human plasma, and their quantification in peripheral blood is complicated by rapid metabolism and artefactual ex vivo formation (44). Alternative strategies, such as quantification in peripheral blood following ex vivo stimulation or in urine, were beyond the scope of the current investigation. Thus, future studies that integrate multiple analytical platforms and sampling strategies will be needed to more precisely discern the association between EETs and CAD extent relative to prostaglandins and a broader array of bioactive lipids.
Recent failures in CAD drug development suggest that innovative approaches are needed to mitigate increasing attrition rates and more successfully translate novel therapies into clinical practice (45).
Compared to the conventional 'one-size fits all' methodology to drug development, a precision medicine approach has the potential to increase the probability of success for promising therapeutic candidates (46).
Although targeted therapies are routinely used in oncology, this strategy has not been readily adopted in CAD. Biomarkers offer considerable promise to prospectively identify subsets of CAD patients at high risk of experiencing a cardiovascular event that exhibit dysfunction in a specific pathway (putative responders), thereby enabling novel therapies that target the pathway to maximize their therapeutic effect and improve outcomes. Our findings offer important insight into the potential therapeutic utility of increasing EETs in obstructive CAD patients predisposed to low EET levels. Importantly, agents that promote the effects of EETs are in early development for a variety of therapeutic indications (47-49). In parallel, technology for the high-throughput quantification of CYP-derived eicosanoids in the clinical setting is advancing (50). Consequently, our results set the foundation for future clinical research in this area, including the rational design of prospective, biomarker-guided interventional studies in targeted subsets of the CAD population (low EET levels) with enriched potential to derive clinical benefit from emerging EET-promoting therapies. follow-up data (N=121) and (b) free plasma EET levels at baseline (tertiles) exclusively within the subset of patients with obstructive CAD (N=63). The log rank P-value (unadjusted) for each Kaplan-Meier curve is provided. Below the curves, the number and frequency of events within each CAD extent and EET tertile group, along with the unadjusted hazard ratio (HR), 95% confidence interval (CI) and P-value, is
provided. Due to the lack of events in those with no apparent CAD at baseline, the no apparent CAD and nonobstructive CAD groups were combined and served as a single reference group. 
